Children born today could see average life expectancy pass 100 years within a generation, healthcare executives
predicted at the
Fortune Leaders Forum in Macau on Tuesday.
Yet the bigger problem may be figuring out how to pay for it.
“The question is not the availability of all these new technologies. It’s how we’re going to make good medical care accessible to millions, and how we’re going to make it affordable as we age,” said Kelvin Loh, group chief healthcare officer at insurer AIA.
One in four people in Asia-Pacific will be over 60 by 2050, up from around one in seven now. That shift will put even more strain on healthcare systems due to a greater incidence of chronic conditions.
AI drugmakers are betting they can ease that burden by tackling aging at its source.
“We might have a chance to stop biological aging,” said Feng Ren, co-CEO of Insilico Medicine. On Monday, the AI drug discovery startup announced that patients taking its experimental fibrosis drug showed signs that their predicted biological age had declined by roughly three years on average.
Loh’s take was more measured: “We may not cure aging, but we are going to extend life.”
Medicine is already turning some terminal diagnoses into manageable ones, Loh added. “Cancer is no more a death sentence,” he said, adding that stage 4 lung cancer patients once given six months to live can live for 10 years or more.
“It’s important that we don’t live longer; we live healthier,” said Keith Choy, president of Asia-Pacific at consumer health company Haleon.
—Danny Vincent